UCB (OTCMKTS:UCBJY) Shares Gap Down – Time to Sell?

UCB SA (OTCMKTS:UCBJY)’s share price gapped down before the market opened on Monday . The stock had previously closed at $151.41, but opened at $144.48. UCB shares last traded at $144.87, with a volume of 1,975 shares changing hands.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Zacks Research downgraded shares of UCB from a “hold” rating to a “strong sell” rating in a research report on Thursday, June 11th. Finally, Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a research note on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

UCB Stock Down 3.4%

The business’s 50-day moving average is $143.51 and its two-hundred day moving average is $147.94. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.